US pharmacy chain
The company, which began in 1962 as a single drugstore in Scranton, Pennsylvania, employs around 45,000 people across more than 2,000 locations. In 2015, it entered the pharmacy benefit manager business, serving as a middleman between insurers and patients that helps process prescriptions. It’s now planning to sell that business, called Elixir, in bankruptcy.
Hit hard by the pandemic, Rite Aid began a series of debt swaps and pay-downs between 2020 and 2022 to try to cut its interest expenses, according to court papers. It also closed around 200 underperforming stores and entered sale-leaseback deals.
To fund itself during the Chapter 11 process, Rite Aid reached a deal with lenders for $3.45 billion in financing, and entered an agreement for Elixir to be acquired by PBM company
MedImpact has agreed to pay $575 million cash plus for Elixir, plus assume certain liabilities, court papers show. The bid serves as a floor for other offers in bankruptcy. Any deal is subject to court approval.
Rite Aid had been battling opioid claims, including the Justice Department
Other national pharmacy chains, including
Rite Aid appointed
The company estimated it had more than 100,000 creditors and said funds would be available for distribution to unsecured creditors.
Rite Aid filed its bankruptcy petitions in Trenton, New Jersey, on Sunday. It is scheduled to appear for the first time in front of US Bankruptcy Judge
Rite Aid is working with A&G Realty Partners to shutter more stores to cut down on rent costs of its more than 2,100 locations as part of the turnaround efforts.
The case is Rite Aid Corp., 23-18993, US Bankruptcy Court for the District of New Jersey.
(Updates with additional details throughout.)
--With assistance from
To contact the reporters on this story:
To contact the editors responsible for this story:
Jeremy Hill, Katerina Petroff
© 2023 Bloomberg L.P. All rights reserved. Used with permission.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
